ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $1 | $1 |
| Enterprise Value | – | $1 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7.8% | 7.2% | 3.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 49.1% | 64.7% | 62.9% | 57.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 26.8% | 18.6% | 24.5% | 7.8% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 10.6% | 4% | 8% | -5.4% |
| EPS Diluted | 1.13 | 0.36 | 0.69 | -0.55 |
| % Growth | 213.9% | -47.8% | 225.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |